Committee Member Employment Consultant Speakers Bureau Ownership/ Partnership/ Principal Personal Research Institutional, Organizational, or Other Financial Bene t Expert Witness Nasrien E. Ibrahim Massachusetts General Hospital Assistant Professor of Medicine, Harvard Medical School; Associate Director, Resynchronization and Advanced Cardiac Therapeutics Program, Massachusetts General Hospital n Roche Diagnostics None None n Boehringer Ingelheim n Novartis None None JoAnn Lindenfeld Vanderbilt University Director, Heart Failure and Transplantation Program n Abbott n AstraZeneca n Boehringer Ingelheim n Edwards Lifesciences n Novartis None None n AstraZeneca None None Frederick A. Masoudi University of Colorado Anschutz Medical Campus Professor of Medicine None None None None None None Shweta R. Motiwala Beth Israel Deaconess Medical Center, Harvard Medical School Instructor in Medicine n Eli Lilly None None n Relypsa None None Estefania Oliveros Temple University Hospital Pulmonary Hypertension, Right Heart Failure and CTEPH Program None None None None None None J. Herbert Patterson University of North Carolina Eshelman School of Pharmacy Professor of Pharmacy and Research Professor of Medicine n Novartis* None None n Amgen n Boehringer Ingelheim n Novartis None None Mary Norine Walsh St. Vincent Heart Center of Indiana Medical Director, Heart Failure and Cardiac Transplantation None None None None None None Alan Wasserman The George Washington University School of Medicine and Health Sciences Eugene Meyer Professor of Medicine; Chairman, Department of Medicine None None None None None None Clyde W. Yancy Northwestern University, Feinberg School of Medicine Vice Dean, Diversity and Inclusion; Magerstadt Professor of Medicine; Chief, Division of Cardiology None None None None None None Quentin R. Youmans Northwestern University Feinberg School of Medicine Fellow, Division of Cardiology, Department of Medicine None None None None None None This table represents the relationships of committee members with industry and other entities that were determined to be relevant to this document. These relationships were reviewed and updated in conjunction with all meetings and/or conference calls of the writing committee during the document development process. 